Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth

被引:35
作者
Yee, Lynn M. [1 ]
Liu, Lilly Y. [1 ]
Sakowicz, Allie [1 ]
Bolden, Janelle R. [1 ]
Miller, Emily S. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chicago, IL 60611 USA
关键词
17-alpha hydroxyprogesterone caproate; adherence; disparities; health services; preterm birth; preterm birth prevention; racial disparities; PROGESTERONE; DELIVERY;
D O I
10.1016/j.ajog.2015.12.054
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Racial/ethnic disparities in preterm birth remain a major public health challenge in the United States. While 17-alpha hydroxyprogesterone caproate (17OHP-C) is recommended for preterm birth prevention in women with a prior preterm birth, non-Hispanic black women continue to experience higher rates of recurrent preterm birth than white women receiving the same treatment. Further investigation of disparities in 17OHP-C use and adherence is warranted. OBJECTIVE: We sought to evaluate whether racial and ethnic disparities exist in the use of and adherence to 17OHP-C within a population of eligible women. STUDY DESIGN: This was a retrospective cohort study of women with a prior spontaneous, singleton preterm birth who were eligible for 17OHP-C for preterm birth prevention and received care at a single institution from 2010 through 2014. Associations between self-identified race/ethnicity (non-Hispanic black vs women in all other racial/ethnic groups) and documented counseling about 17OHP-C, receipt of any 17OHP-C, and adherence to 17OHP-C administration were each estimated by bivariable analysis and multivariable logistic regression. Adherence to 17OHP-C was defined as not >1 missed dose, initiation <20 weeks' gestational age, and continuation until 37 weeks or delivery. RESULTS: Of 472 women who were clinically eligible for 17OHP-C, 72% (N = 296) had documented 17OHP-C counseling and 48.9% (N = 229) received 17OHP-C. There were no differences in likelihood of 17OHP-C counseling or receipt of 17OHP-C based on race/ethnicity. While overall 83% (N = 176) of women were adherent to 17OHP-C, only 70% (N = 58) of non-Hispanic black women were adherent, compared to 91% (N = 118) of all other women (P < .001). Non-Hispanic black women had more missed doses (2.4 vs 0.4 doses, P < .001) and later initiation of care (12.0 vs 10.2 weeks, P < .001) than women in other racial/ethnic groups. After adjustment for potential confounders, non-Hispanic black women were significantly less likely to be adherent to 17OHP-C (adjusted odds ratio, 0.16; 95% confidence interval, 0.04-0.65). A significant interaction between non-Hispanic black race/ethnicity and public insurance was identified (adjusted odds ratio, 0.16; 95% confidence interval, 0.05-0.52). CONCLUSION: In a diverse cohort of women eligible for preterm birth prevention, non-Hispanic black women are at an increased risk of nonadherence to 17OHP-C. Non-Hispanic black women with public insurance are at a particularly increased risk of nonadherence.
引用
收藏
页数:6
相关论文
共 13 条
[1]  
[Anonymous], 2012, Acog Practice Bulletin No. 130. Obstet Gynecol, V120, P964, DOI [DOI 10.1097/AOG.0B013-3182723B1B, DOI 10.1097/AOG.0B013E3182723B1B]
[2]  
Bailit JL, 2007, J REPROD MED, V52, P280
[3]  
Berghella V, 2012, AM J OBSTET GYNECOL, V206, P86
[4]   Preterm birth 1 - Epidemiology and causes of preterm birth [J].
Goldenberg, Robert L. ;
Culhane, Jennifer F. ;
Iams, Jay D. ;
Romero, Roberto .
LANCET, 2008, 371 (9606) :75-84
[5]   Pregnancy Outcomes of Managed Medicaid Members Prescribed Home Administration of 17 α-Hydroxyprogesterone Caproate [J].
Lucas, Brad ;
Poole-Yaeger, Amy ;
Istwan, Niki ;
Stanziano, Gary ;
Rhea, Debbie ;
Mason, Mary .
AMERICAN JOURNAL OF PERINATOLOGY, 2012, 29 (07) :489-495
[6]  
Mason Mary V, 2008, Manag Care, V17, P47
[7]   Does progesterone treatment influence risk factors for recurrent preterm delivery? [J].
Meis, PJ ;
Klebanoff, M ;
Dombrowski, MP ;
Sibai, BM ;
Leindecker, S ;
Moawad, AH ;
Northen, A ;
Iams, JD ;
Varner, MW ;
Caritis, SN ;
O'Sullivan, MJ ;
Miodovnik, M ;
Leveno, K ;
Conway, D ;
Wapner, RJ ;
Carpenter, M ;
Mercer, B ;
Ramin, SM ;
Thorp, JM ;
Peaceman, AM ;
Gabbe, S .
OBSTETRICS AND GYNECOLOGY, 2005, 106 (03) :557-561
[8]   Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [J].
Meis, PJ ;
Klebanoff, M ;
Thom, E ;
Dombrowski, MP ;
Sibai, B ;
Moawad, AH ;
Spong, CY ;
Hauth, JC ;
Miodovnik, M ;
Varner, MW ;
Leveno, KJ ;
Caritis, SN ;
Iams, JD ;
Wapner, RJ ;
Conway, D ;
O'Sullivan, MJ ;
Carpenter, M ;
Mercer, B ;
Ramin, SM ;
Thorp, JM ;
Peaceman, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2379-2385
[9]   Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate [J].
Rebarber, Andrei ;
Ferrara, Lauren A. ;
Hanley, Maryellen L. ;
Istwan, Niki B. ;
Rhea, Debbie J. ;
Stanziano, Gary J. ;
Saltzman, Daniel H. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (03) :224-225
[10]   Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting [J].
Rittenberg, Charles ;
Sullivan, Scott ;
Istwan, Niki ;
Rhea, Debbie ;
Stanziano, Gary ;
Newman, Roger .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (03) :262.e1-262.e4